Forbes December 19, 2023
Could CAR T Therapy, an innovative treatment for certain blood cancers, cause lymphoma? Reports from clinical trials and data released after product approval suggest that the treatment could trigger the development of cancerous T cells in rare cases. Although the therapy’s benefits continue to outweigh this potential danger, the FDA recently announced an investigation on all six federally-approved CAR T therapies to understand this risk and evaluate the need for regulatory action.
Potential Culprits
Chimeric Antigen Receptor T cell therapy is a valuable therapeutic for patients with relapsed/refractory B-cell derived lymphomas, leukemias and multiple myeloma. The intervention works by using a patient’s own immune cells to treat their cancer.
White blood cells called T cells are extracted from the patient,...
Today's Sponsors
Today's Sponsor